[The overexpression of NCAM (CD56) in human hearts is specific for ischemic damage]
S Gattenlöner1, C Waller, G Ertl
1Institut für Pathologie der Universitat Würzburg, Würzburg, Germany.
Abstract:
The main reason for myocardial dysfunction is chronical myocardial ischemia. Recently we could show, that NCAM (CD56), a neural cell adhesion molecule and member of the immunoglobuline superfamily, and the transcription factor AML1 (RUNX1) are overexpressed in chronic ischemic human heart failure compaired to normal hearts. Here we demonstrate, that the overexpression of NCAM (CD56) is specific for ischemic damage as compaired to other heart diseases including congestive cardiomyopathy, hypertrophic obstrutive cardiomyopathy, myocarditis and sarcoidosis. Concerning the transcriptional regulation of NCAM (CD56) by AML1 (RUNX1) we isolated 3 novel isoforms of AML 1 (RUNX1) with different transactivating function, that might be a regulatory element of the NCAM (CD56) overexpression in chronical myocardial ischemia.
Insights
Neural cell adhesion molecule (NCAM) and transcription factor AML1 are overexpressed in chronic ischemic heart failure. This NCAM overexpression is specific to ischemic damage, suggesting a regulatory role for novel AML1 isoforms.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Chronic myocardial ischemia is a primary cause of myocardial dysfunction.
- Neural cell adhesion molecule (NCAM, CD56) and transcription factor AML1 (RUNX1) are known to be overexpressed in chronic ischemic human heart failure.
- NCAM is a neural cell adhesion molecule and a member of the immunoglobulin superfamily.
Purpose of the Study:
- To investigate the specificity of NCAM (CD56) overexpression in ischemic heart damage compared to other cardiac diseases.
- To explore the transcriptional regulation of NCAM (CD56) by AML1 (RUNX1) in the context of chronic myocardial ischemia.
- To identify novel isoforms of AML1 (RUNX1) and their potential role in regulating NCAM (CD56) expression.
Main Methods:
- Comparative analysis of NCAM (CD56) and AML1 (RUNX1) expression in human heart failure samples.
- Histopathological and molecular assessments to differentiate ischemic damage from other cardiomyopathies (congestive, hypertrophic obstructive, myocarditis, sarcoidosis).
- Isolation and characterization of novel AML1 (RUNX1) isoforms and assessment of their transactivating functions.
Main Results:
- Overexpression of NCAM (CD56) was found to be specific to ischemic heart damage.
- NCAM (CD56) overexpression was not observed in other heart diseases like congestive cardiomyopathy, hypertrophic obstructive cardiomyopathy, myocarditis, and sarcoidosis.
- Three novel isoforms of AML1 (RUNX1) with varying transactivating capabilities were identified.
Conclusions:
- NCAM (CD56) overexpression is a specific biomarker for ischemic myocardial damage.
- Novel AML1 (RUNX1) isoforms may play a regulatory role in the overexpression of NCAM (CD56) in chronic myocardial ischemia.
- These findings provide insights into the molecular mechanisms underlying ischemic heart failure.
